Nov 10, 2009 | Drugs.com
Independent Study Utilizing Cyclic Levulan PDT Finds 95 Percent...
WILMINGTON, Mass., Nov. 10 /PRNewswire/ -- The results of an independent investigator study just published in the online version of Dermatologic Surgery demonstrate that LevulanA Photodynamic Therapy may reduce the rate of recurrence of squamous cell carcinomas in solid organ transplant recipients , a population with a high incidence of nonmelanoma ...
DUSA Pharmaceuticals Named to Deloitte's 2009 Technology Fast 500...
DUSA Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on dermatology, announced today that it has been named to Deloitte's Technology Fast 500 list.
Customer Interaction Solutions
VRAZ, WRLS, DUSA, CFS, AMS, INMD Expected To Be Lower After Earnings Releases on Thursday
BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released Thursday, August 6th and determining how the stocks have performed after their last 12 quarterly, 6 quarterly and August earnings reports.
Also on Topix